Former “Real Housewives of Beverly Hills” star Teddi Mellencamp has been sharing her cancer journey since her 2022 melanoma ...

But Caprario didn’t experience that until the final stages of her crisis. Instead, she had mainly atypical warning signs, which tend to occur more in women than men, says Dr. Linus Wodi ...

These people are at a slightly increased risk of melanoma, says Dr. Larocca. If it’s moderately to severely atypical, it could suggest that the mole may one day become a melanoma. Severely atypical ...

Histologic examination showed proliferation of atypical melanocytes devoid of ... The patient was diagnosed with lentiginous maligna melanoma with Clark's level not less than II and Breslow's ...

Professor Georgina Long discusses the "phenomenal" breakthrough melanoma treatment that is having a life-saving impact after new data confirmed it is achieving long-term disease control.

Property News: The new luxury Kirribilli penthouse with a $65m price tag. © 2025 Nine Entertainment Co.

A groundbreaking clinical trial has proved that the majority of melanoma patients whose cancer has spread to the brain can be “cured” when given combination immunotherapy as a first-line ...

Legionella infection is an atypical cause of community-acquired pneumonia. Referred to as legionnaires' disease, it presents with fever, fatigue, respiratory symptoms, and sometimes diarrhea.

She is scheduled for some tests. Her primary care physician believes it might be melanoma. What is melanoma? What treatment options are available, and is surgery necessary? Have there been recent ...

On Thursday, BMS revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely resected stage III and stage IV melanoma did not achieve its primary endpoint.

Real Housewives star Teddi Mellencamp, 43, has been diagnosed with multiple brain tumors potentially linked to a prior melanoma. Experts highlight that melanoma can spread rapidly and reach the brain, ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts. Bristol Myers ...